solifenacin succinate

Also found in: Dictionary.
Related to solifenacin succinate: Tamsulosin, Vesicare

solifenacin succinate

VESIcare, Vesicare (UK)

Pharmacologic class: Anticholinergic

Therapeutic class: Renal and genitourinary agent

Pregnancy risk category C


Antagonizes muscarinic receptors, reducing urinary bladder smooth-muscle contractions


Tablets: 5 mg, 10 mg

Indications and dosages

Overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency

Adults: 5 mg P.O. daily initially; may increase to 10 mg P.O. daily if well tolerated

Dosage adjustment

• Moderate hepatic impairment
• Severe renal impairment
• Concurrent use of potent CYP3A4 inhibitors (such as ketoconazole)


• Hypersensitivity to drug or its components
• Urinary retention
• Gastric retention
• Uncontrolled angle-closure glaucoma


Use cautiously in:
• hepatic or renal impairment, bladder outflow obstruction, decreased GI motility, GI obstructive disorder, controlled angle-closure glaucoma, congenital or acquired QT interval prolongation
• increased risk of urinary retention or heat prostration
• pregnant or breastfeeding patients
• children (safety and efficacy not established).


• Give with liquids, with or without food. Make sure patient swallows tablet whole.

Adverse reactions

CNS: dizziness, depression, fatigue, asthenia

CV: hypertension

EENT: dry eyes, blurred vision, dry throat, pharyngitis

GI: nausea, vomiting, constipation, upper abdominal pain, dyspepsia, dry mouth

GU: urinary tract infection, urinary retention

Respiratory: cough

Skin: dry skin, rash, pruritus

Other: influenza, leg or foot edema


Drug-drug.Anticholinergics: increased frequency or severity of adverse reactions

CYP3A4 inhibitors (such as ketoconazole): increased solifenacin blood level

Patient monitoring

• Monitor GI, renal, and hepatic function frequently.
• Monitor patient for ophthalmic disorders, especially angle-closure glaucoma. If present, stop drug until condition stabilizes.

Patient teaching

• Instruct patient to take drug with liquids, with or without food, and to swallow tablet whole.
• Advise patient to contact prescriber if severe abdominal pain or constipation lasting 3 or more days occurs.
• Caution patient to avoid driving and other hazardous activities until drug effects are known.
• Advise patient of risk for heat prostration; describe symptoms.
• Instruct patient to consult prescriber before taking over-the-counter products such as antihistamines because these may increase risk of side effects.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

References in periodicals archive ?
In fact, a new medication, called Vesicare, also known as solifenacin succinate tablets, has just been approved by the FDA to help treat these symptoms.
SAN DIEGO, July 29 /PRNewswire/ -- Solifenacin succinate, a once-daily oral antimuscarinic agent in development for the treatment of overactive bladder (OAB), significantly reduced urgency episodes in a pooled analysis of four pivotal trials involving more than 2800 patients, according to data presented today at the annual meeting of the American Urogynecologic Society (AUGS).
Solifenacin succinate is a once-daily oral muscarinic antagonist in development for the treatment of overactive bladder that acts to block the receptors in the smooth muscle of the bladder.
Solifenacin succinate, a once-daily oral antimuscarinic agent in development, significantly reduced the three key symptoms of overactive bladder (OAB) -- urgency, frequency, and incontinence -- in four pooled trials involving 2,466 women, according to data presented today at the annual meeting of the American College of Obstetrics and Gynecology (ACOG).
Combined with the significant reductions in frequency and urge incontinence, solifenacin succinate shows promise in offering benefits to patients with OAB.
New Antimuscarinic Agent, Solifenacin Succinate, Reduces Urgency Episodes in Overactive Bladder:
Solifenacin succinate 10 mg once daily significantly improves symptoms of overactive bladder.
Solifenacin succinate, to be co-promoted with Yamanouchi, is being developed to treat overactive bladder, relieving urinary frequency, incontinence, and urgency.